Fig. 4
Reproduced from J Am Coll Cardiol. 2022, volume 79(17), pages e263–e421, Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Copyright (2022), with permission from The American Heart Association, Inc., The American College of Cardiology Foundation, and The Heart Failure Society of America
Recommendations for patients with preserved LVEF (≥ 50%), per AHA/ACC/HFSA 2022 [8]. Medication recommendations for HFpEF are displayed. ARB angiotensin receptor blocker, ARNI angiotensin receptor-neprilysin inhibitor, HF heart failure, HFpEF heart failure with preserved ejection fraction, LVEF left ventricular ejection fraction, MRA mineralocorticoid receptor antagonist, SGLT2i sodium-glucose cotransporter-2 inhibitor. *Greater benefit in patients with LVEF closer to 50%.